{
    "id": 9184,
    "fullName": "WT1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "WT1 positive indicates the presence of the WT1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7490,
        "geneSymbol": "WT1",
        "terms": [
            "WT1",
            "AWT1",
            "GUD",
            "NPHS4",
            "WAGR",
            "WIT-2",
            "WT33"
        ]
    },
    "variant": "positive",
    "createDate": "07/17/2015",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14933,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ATA520 (WT1-CTL) treatment resulted in complete remission lasting over 2 years in 2 out of 7 patients with WT1-positive plasma cell leukemia (n=3) or multiple myeloma (n=4) (Blood 2015 126(23):98).",
            "molecularProfile": {
                "id": 9114,
                "profileName": "WT1 positive"
            },
            "therapy": {
                "id": 7192,
                "therapyName": "ATA520",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11813,
                    "pubMedId": null,
                    "title": "Wilms\u00b4Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches",
                    "url": "http://www.bloodjournal.org/content/126/23/98?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12811,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Galinpepimut-S resulted in a progression-free survival rate of 45% at 1 year compared to 33% in the control arm in patients with malignant pleural mesothelioma expressing WT1, however, the study was not powered for a comparison between arms (PMID: 28972039).",
            "molecularProfile": {
                "id": 9114,
                "profileName": "WT1 positive"
            },
            "therapy": {
                "id": 6676,
                "therapyName": "Galinpepimut-S",
                "synonyms": null
            },
            "indication": {
                "id": 7474,
                "name": "malignant pleural mesothelioma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10744,
                    "pubMedId": 28972039,
                    "title": "A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28972039"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9114,
            "profileName": "WT1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}